"The U.S. Food and Drug Administration today approved Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.
Precursor B-cell A"...
High doses of LEUSTATIN have been associated with: irreversible neurologic toxicity (paraparesis/quadriparesis), acute nephrotoxicity, and severe bone marrow suppression resulting in neutropenia, anemia and thrombocytopenia (see WARNINGS). There is no known specific antidote to overdosage. Treatment of overdosage consists of discontinuation of LEUSTATIN, careful observation and appropriate supportive measures. It is not known whether the drug can be removed from the circulation by dialysis or hemofiltration.
LEUSTATIN Injection is contraindicated in those patients who are hypersensitive to this drug or any of its components.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/16/2016
Additional Leustatin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.